Ali McBride, PharmD, MS, BCOP, is the Clinical Coordinator of Hematology/Oncology at The University of Arizona Cancer Center. Currently serving on the Board of the Association of Community Cancer Centers (ACCC), Dr. McBride also chairs the Awards Selection Committee as well as the Corporate Development Committee. In addition to being a long-time ACCC member, Dr. McBride has been actively involved with the American Society of Health-System Pharmacists (ASHP) and the Hematology/Oncology Pharmacy Association (HOPA).
Dr. McBride has been working on oncology drug shortages and has testified on behalf of HOPA at the U.S. Food and Drug Administration (FDA) Drug Shortage Workshop; presented on behalf of ACCC at the Washington, D.C., Congressional Session; and was an invited member of the ASHP Drug Shortage Stakeholders Meeting. Dr. McBride is also actively involved with biosimilar regulation and the pharmacoeconomic impact of biosimilars into the U.S. marketplace. He currently serves as a working group member for HOPA on its biosimilar committee. In addition, he serves on the National Quality Forum Cancer Standing Committee. He has published numerous articles on drug shortages, oral chemotherapy adherence, stem cell transplant, and biosimilar implementation into the U.S. healthcare market.